Intellia Therapeutics, Inc. (NTLA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$12.74+0.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NTLA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -5.6% |
| Our one-year growth estimate | diamond | 70.3% |
Growth built into the price is above our model estimate.
The price assumes 75.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
NTLA — credit agreement
Dated 2026-09-04
Entry into a Material Definitive Agreement. On September 4, 2026 (the “Closing Date”), Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent (“Administrative Agent”). OrbiMed Royalty & Credit Opportunities IV, LP, and OrbiMed Royalty & Credit Opportunities V, LP, are the initial Lenders. The Credit…
Why it matters: If healthcare sector revenue growth speeds up, it could benefit Intellia. This may improve investor sentiment.
Supportive ifHealthcare sector revenue growth is speeding up again. This shows a stronger market.
Worry ifHealthcare sector revenue growth is slowing down. This means there are ongoing challenges.
Why it matters: Good results could help get the drug approved. They may also make investors feel better. Bad results could raise worries about the treatment.
Watch forA press release confirming positive results from the Phase 3 HAELO trial of Lonvo-z.
Also watch forA press release stating that the Phase 3 HAELO trial did not meet its primary endpoint.
Why it matters: The earnings report will show how well Intellia is doing financially.
Watch forEarnings report shows revenue growth and positive guidance.
Also watch forThe earnings report shows falling revenue and bad guidance.
Why it matters: Extending the cash runway into 2028 is key for funding ongoing projects. A failure to extend could signal financial instability.
Supportive ifAn announcement that cash will last until 2028.
Worry ifA statement indicating that the cash runway will not extend into 2028.
Why it matters: News about the partnership could mean new funding or chances to work together. No news might show that progress has stopped.
Supportive ifA press release about new developments or funding from the partnership.
Worry ifNo news or bad news about the partnership.
Why it matters: Updates on cash position can show the company's financial health. This affects funding for operations into 2028.
Watch forThe company has more than $500 million in cash after the public offering.
Also watch forThe company has less than $500 million in cash. This raises funding concerns.
Why it matters: Court results could change when Lonvo-z gets approved and enters the market. Good results may help the drug move forward.
Watch forA court decision that supports Intellia in the Lonvo-z case.
Also watch forA court decision went against Intellia. This slows down Lonvo-z's development.
Why it matters: Further data could strengthen the case for lonvo-z and support its market potential. Positive results can boost investor confidence.
Supportive ifThe company shares more good data from the HAELO trial at a big conference.
Worry ifThe data shows worse results than what was reported before.
Why it matters: It is important to extend the cash runway to 2028. This helps fund ongoing projects. It also affects financial stability.
Supportive ifManagement shares news of a successful funding round or partnership. This extends cash runway.
Worry ifManagement says cash runway is shorter than expected. Funding problems may come up.
Why it matters: Enrollment progress is key for the nex-z program. It helps strengthen the overall pipeline.
Supportive ifThe company says patient enrollment in the MAGNITUDE-2 trial will finish by the end of Q3 2026.
Worry ifEnrollment in the MAGNITUDE-2 trial is delayed or falls short of expectations.
Why it matters: FDA acceptance is key for lonvo-z's path to market. A successful acceptance supports the potential launch in 2027.
Supportive ifThe FDA accepts the biologics license application for lonvo-z in late 2026.
Worry ifFDA does not accept the BLA, delaying the launch timeline.
Why it matters: Finishing enrollment is key for nex-z’s development in ATTR amyloidosis. It shows progress in the trial.
Supportive ifEnrollment in the MAGNITUDE-2 trial is completed by the end of 2026.
Worry ifEnrollment is delayed past the second half of 2026.
Why it matters: More positive data can help lonvo-z get approved and accepted in the market.
Supportive ifNew positive data from lonvo-z trials will be shared at upcoming meetings.
Worry ifNew data shows lonvo-z is less effective or has safety issues.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$251 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $844 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,127 loss on $10,000 · 71.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.